Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population
Primary Purpose
Signs and Symptoms, Respiratory
Status
Unknown status
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
busulfan
respiratory function tests
pharmacokinetics, done during the treatment
Sponsored by
About this trial
This is an interventional treatment trial for Signs and Symptoms, Respiratory focused on measuring Busulfan, pharmacokinetic, respiratory function assessment, Busulfan pharmacokinetic and respiratory function tests
Eligibility Criteria
Inclusion Criteria: Patients above 3 years old treated by busulfan or TBI in their conditioning regimens before allograft or busulfan in high dose chemotherapeutic regimens followed by autograft will be included after parents informed assent.
Sites / Locations
- Service d'Explorations Fonctionelles Respiratoires - Hôpital CivilRecruiting
- Service de Pédiatrie Onco-Hématologie - Hôpital de HautepierreRecruiting
Outcomes
Primary Outcome Measures
Determination of respiratory side effect frequency in the two years follow up of allograft or autograft treated with busulfan
Secondary Outcome Measures
Comparison to respiratory side effect frequency with TBI conditioning regimen
Busulfan pharmacokinetics
Establish a potential link between respiratory side effects and busulfan pharmacokinetics
Full Information
NCT ID
NCT00328029
First Posted
May 18, 2006
Last Updated
February 24, 2009
Sponsor
University Hospital, Strasbourg, France
1. Study Identification
Unique Protocol Identification Number
NCT00328029
Brief Title
Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population
Official Title
Assessment of Respiratory Functions After a Conditioning Regimen With Busulfan for Allograft or Autograft in a Unicenter Pediatric and Prospective Population
Study Type
Interventional
2. Study Status
Record Verification Date
February 2009
Overall Recruitment Status
Unknown status
Study Start Date
July 2006 (undefined)
Primary Completion Date
January 2012 (Anticipated)
Study Completion Date
June 2012 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
University Hospital, Strasbourg, France
4. Oversight
5. Study Description
Brief Summary
Recently, several conditioning regimens did not include total body irradiation (TBI) anymore, especially in the case of young children due to cognitive sequelae and late effects on growth and height. Thus, such effective chemotherapy conditioning regimens were developed to avoid these complications. Busulfan is one of the major drugs used in these treatments, but, is also administered in high dose chemotherapy followed by autograft. In both situations, long term pulmonary side effects were diagnosed in a few cases. Even if the occurrence is not very frequent, the clinical management is a real challenge regarding the reduced quality of life and life expectancy of these patients. Up to now, no correlation was done between respiratory sequelae and busulfan pharmacokinetics. Hence, in the investigators' pediatric onco-hematological unit, a prospective study will begin and last three years to assess the respiratory side effects due to busulfan and their potential links with individual drug pharmacokinetic measures. These results will be compared to patients treated with TBI during the same period of time.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Signs and Symptoms, Respiratory
Keywords
Busulfan, pharmacokinetic, respiratory function assessment, Busulfan pharmacokinetic and respiratory function tests
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
35 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
busulfan
Intervention Description
5mg/kg/day (oral route : 4 doses/day for 4 days)
Intervention Type
Procedure
Intervention Name(s)
respiratory function tests
Other Intervention Name(s)
before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
Intervention Description
respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
Intervention Type
Procedure
Intervention Name(s)
pharmacokinetics, done during the treatment
Intervention Description
12 blood collections :
after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.
3 hours after 2nd taken of Busulfan
3 hours after 3rd taken of Busulfan
3 hours after 4th taken of Busulfan
3 hours after 5th taken of Busulfan
3 hours after 6th taken of Busulfan.
Primary Outcome Measure Information:
Title
Determination of respiratory side effect frequency in the two years follow up of allograft or autograft treated with busulfan
Time Frame
before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
Secondary Outcome Measure Information:
Title
Comparison to respiratory side effect frequency with TBI conditioning regimen
Time Frame
before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
Title
Busulfan pharmacokinetics
Time Frame
after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h ; 3 h after 2nd Busulfan taken ; 3 hours after 3rd Busulfan taken ; 3 h after 4st Busulfan taken ;3 h after 5st Busulfan taken ;3 h after 6st Busulfan taken
Title
Establish a potential link between respiratory side effects and busulfan pharmacokinetics
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients above 3 years old treated by busulfan or TBI in their conditioning regimens before allograft or busulfan in high dose chemotherapeutic regimens followed by autograft will be included after parents informed assent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Patrick Lutz, MD
Phone
3.33.88.12.80.90
Email
patrick.lutz@chru-strasbourg.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Natacha Entz-Werle, MD
Phone
3.33.88.12.80.99
Email
natacha.entz-werle@chru-strasbourg.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick Lutz, MD
Organizational Affiliation
Service de Pédiatrie Onco-Hématologie - Hôpital de Hautepierre
Official's Role
Study Director
Facility Information:
Facility Name
Service d'Explorations Fonctionelles Respiratoires - Hôpital Civil
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Charloux Anne, MD
Phone
3.33.88.11.61.22
Email
anne.charloux@chru-strasbourg.fr
First Name & Middle Initial & Last Name & Degree
Oswald Monique, MD
Phone
3.33.88.11.68.61
Email
monique.oswald@chru-strasbourg.fr
Facility Name
Service de Pédiatrie Onco-Hématologie - Hôpital de Hautepierre
City
Strasbourg
ZIP/Postal Code
67098
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrick Lutz, MD
Phone
3.33.88.12.80.90
Email
patrick.lutz@chru-strasbourg.fr
First Name & Middle Initial & Last Name & Degree
Natacha Entz-Werle, MD
Phone
3.33.88.12.80.99
Email
natacha.entz-werle@chru-strasbourg.fr
First Name & Middle Initial & Last Name & Degree
Patrick Lutz, MD
First Name & Middle Initial & Last Name & Degree
Natacha Entz-Werle, MD
First Name & Middle Initial & Last Name & Degree
Nadine COJEAN, MD
First Name & Middle Initial & Last Name & Degree
Sophie BAYART, MD
12. IPD Sharing Statement
Learn more about this trial
Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population
We'll reach out to this number within 24 hrs